Although clinical research is still in its early stages, practice-based reports from individuals using microdosing for this purpose suggest potential benefits in managing alcohol, opioid, stimulant, and tobacco use disorders, while minimize the risks of weight loss, gastrointestinal side effects, and hypoglycemia
Chen Y, et al
Some medications reduce alcohols rewarding effects (naltrexone and, potentially, GLP-1 medications)
Indeed, both in rodents and humans, GLP-1 infusion increased fractional sodium excretion [20], which has been linked to the finding that sodium is more rapidly excreted following an oral versus equivalent IV sodium load in a number of experimental studies in healthy individuals, independent of factors such as atrial natriuretic peptide (ANP) and aldosterone [22]
This finding, together with recent guideline updates, may explain the improved glycemic control observed in the later study period